Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment ... MarketWatch (press release) GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in combination with rituximab in previously treated chronic lymphocytic leukemia (CLL) patients. |
